The Use of Morphology-Directed Targeted Immunosuppression With Dupilumab in Cutaneous Immunotherapy Related Adverse Events.
作者信息
Dulmage Brittany, Kaffenberger Benjamin H
机构信息
Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
出版信息
Int J Dermatol. 2025 Oct;64(10):1770-1771. doi: 10.1111/ijd.17956. Epub 2025 Jul 17.
Abstract
摘要
相似文献
1
The Use of Morphology-Directed Targeted Immunosuppression With Dupilumab in Cutaneous Immunotherapy Related Adverse Events.在皮肤免疫治疗相关不良事件中使用度普利尤单抗进行形态学导向的靶向免疫抑制。
Int J Dermatol. 2025 Oct;64(10):1770-1771. doi: 10.1111/ijd.17956. Epub 2025 Jul 17.
2
Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series.度普利尤单抗治疗大疱性类天疱疮有效性和安全性的真实世界评估：一项前瞻性队列多中心病例系列研究
Br J Dermatol. 2025 Feb 18;192(3):501-509. doi: 10.1093/bjd/ljae403.
3
Dupilumab for the Treatment of Cutaneous Graft-Versus-Host Disease: A Systematic Review and Individual Patient Data Meta-Analysis.度普利尤单抗治疗皮肤移植物抗宿主病：一项系统评价和个体患者数据荟萃分析
Transplant Cell Ther. 2025 Aug 28. doi: 10.1016/j.jtct.2025.08.021.
4
Dupilumab for the Treatment of Cutaneous Immune-Related Adverse Events: A Systematic Review.度普利尤单抗治疗皮肤免疫相关不良事件的系统评价
Int J Dermatol. 2025 Oct;64(10):1825-1832. doi: 10.1111/ijd.17850. Epub 2025 May 15.
5
Cutaneous T Cell Lymphoma Following Dupilumab Therapy in Patients with Atopic Dermatitis: Clinical Review and Recommendations.度普利尤单抗治疗特应性皮炎患者后发生的皮肤T细胞淋巴瘤：临床综述与建议
Am J Clin Dermatol. 2025 May 26. doi: 10.1007/s40257-025-00955-7.
6
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.针对嗜酸性粒细胞计数提示 2 型炎症的 COPD，应用度普利尤单抗。
N Engl J Med. 2023 Jul 20;389(3):205-214. doi: 10.1056/NEJMoa2303951. Epub 2023 May 21.
7
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中，度普利尤单抗为中重度特应性皮炎成人患者提供了长达 4 年的可接受安全性和持续疗效。
Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3.
8
Reduction of Rescue Treatment With Dupilumab for Chronic Rhinosinusitis With Nasal Polyps in Japan.日本使用度普利尤单抗减少鼻息肉慢性鼻窦炎的挽救治疗
Laryngoscope. 2025 Sep;135(9):3093-3103. doi: 10.1002/lary.32171. Epub 2025 Apr 21.
9
Exploring dupilumab for asthma: from mechanistic insights to clinical outcomes, safety, and cost-effectiveness.探索度普利尤单抗用于治疗哮喘：从机制洞察到临床疗效、安全性及成本效益
Front Pharmacol. 2025 Aug 6;16:1631321. doi: 10.3389/fphar.2025.1631321. eCollection 2025.
10
Systemic treatments for eczema: a network meta-analysis.湿疹的全身治疗：一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Sep 14;9(9):CD013206. doi: 10.1002/14651858.CD013206.pub2.
本文引用的文献
1
Dupilumab for the Treatment of Cutaneous Immune-Related Adverse Events: A Systematic Review.度普利尤单抗治疗皮肤免疫相关不良事件的系统评价
Int J Dermatol. 2025 Oct;64(10):1825-1832. doi: 10.1111/ijd.17850. Epub 2025 May 15.
2
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024.NCCN 指南®洞察：免疫治疗相关毒性的管理，版本 2.2024。
J Natl Compr Canc Netw. 2024 Nov;22(9):582-592. doi: 10.6004/jnccn.2024.0057.
3
Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials.皮质类固醇类药物治疗免疫相关不良事件及检查点抑制剂疗效：六项临床试验分析。
J Clin Oncol. 2024 Nov;42(31):3713-3724. doi: 10.1200/JCO.24.00191. Epub 2024 Aug 7.
4
Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management.使用多国多机构皮肤免疫相关不良反应和管理登记处来检测新型疗法。
Int J Dermatol. 2023 Aug;62(8):1020-1025. doi: 10.1111/ijd.16714. Epub 2023 May 19.
5
No association between dupilumab use and short-term cancer development in atopic dermatitis patients.度普利尤单抗的使用与特应性皮炎患者短期癌症发生之间无关联。
J Allergy Clin Immunol Pract. 2023 May;11(5):1548-1551. doi: 10.1016/j.jaip.2022.12.018. Epub 2022 Dec 26.
Zotero 插件